-

2seventy bio Announces Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy.

  • Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy
    • September 21, 2021, 11:00am-12:00pm ET
  • Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy
    • September 22, 2021, 1:00-2:00pm ET

To access the live webcasts and dial-in information for 2seventy bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

Contacts

Investors & Media

Investors:

Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com

Media:

Jenn Snyder, 617-448-0281
jsnyder@bluebirdbio.com

Industry:

bluebird bio

NASDAQ:BLUE
Release Versions
English

Contacts

Investors & Media

Investors:

Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com

Media:

Jenn Snyder, 617-448-0281
jsnyder@bluebirdbio.com

More News From bluebird bio

Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. and the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its wholly owned subsidiary, SPIMACO Bio, today announced an exclusive collaboration and license agreement for the development, commercialization, and localized manufacturing of LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and across the broader Middle East. LYFGENIA and ZYNTEGLO are first-in-class, one-time gene addition cell therapies for the tre...

Genetix Announces 2025 Commercial Performance Results and Outlines 2026 Strategic Priorities

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the market leader in genetic therapies for hemoglobinopathies in the U.S., today announced commercial performance results from 2025 and outlined the company’s strategic priorities for 2026. “2025 was a groundbreaking year for our Company on many fronts. New leadership rebranded the Company to Genetix Biotherapeutics, delivered strong revenue growth, increased patient demand, and achieved its first ever profitable quarter,” said D...

Genetix Presents Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for...
Back to Newsroom